Outlook Therapeutics

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.

CEO

C. Russell Trenary

CEOC. Russell Trenary

Employees

Employees9

Headquarters

Iselin, New Jersey

HeadquartersIselin, New Jersey

Founded

2010

Founded2010

Employees

Employees9

OTLK Key Statistics

Market cap

246.58M

Market cap246.58M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

284.11K

Average volume284.11K

High today

$1.10

High today$1.10

Low today

$1.01

Low today$1.01

Open price

$1.07

Open price$1.07

Volume

469.82K

Volume469.82K

52 Week high

$2.12

52 Week high$2.12

52 Week low

$0.6839

52 Week low$0.6839

OTLK News

Yahoo Finance 3d

Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference - Yahoo Finance

Outlook Therapeutics, Inc. Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to participate in a live moderated panel discussion on T...

OTLK Earnings

-$0.09

-$0.06

-$0.03

$0.00

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Dec 22, Pre-Market

ActualExpected Dec 22, Pre-Market